雾化氯胺酮用于急诊科急性疼痛管理:系统评价与Meta分析
该系统评价与Meta分析检索Ovid CENTRAL、EMBASE和MEDLINE数据库(建库至2025年1月),纳入13项研究,评估雾化氯胺酮的镇痛疗效与不良事件发生率。4项RCT(n=601)显示雾化氯胺酮与静脉吗啡在30分钟疼痛缓解无差异(MD 0.28,95%CI -0.18至0.73),补救镇痛率相似(16.9% vs 17.4%)。11项研究报告无严重事件,非严重不良事件无差异(氯胺酮39.1% vs 对照37.8%)。结局证据置信度被评为极低。
要点
- 4项RCT(n=601)显示雾化氯胺酮与静脉吗啡在30分钟疼痛缓解无差异(MD 0.28,95%CI -0.18至0.73),补救镇痛率相似(16.9% vs 17.4%)。
- 11项研究报告无严重事件,非严重不良事件发生率氯胺酮39.1% vs 对照37.8%,无差异。
- 8项RCT中雾化氯胺酮与活性对照疗效等效。
- 所有结局的证据置信度经GRADE评为极低。
适用人群与场景
- 急诊科急性疼痛条件患者;院前环境亦涉及氯胺酮亚解离剂量使用。
研究设计与关键结果
- 系统评价与Meta分析,纳入13项研究(RCT和观察性研究),检索Ovid CENTRAL、EMBASE和MEDLINE建库至2025年1月。
- 4项RCT(n=601)显示雾化氯胺酮与静脉吗啡在30分钟疼痛缓解无差异,MD 0.28(95%CI -0.18至0.73),补救镇痛率16.9% vs 17.4%。
- 8项RCT中雾化氯胺酮与活性对照疗效等效。
- 11项研究报告无严重事件,非严重不良事件发生率氯胺酮39.1% vs 对照37.8%,无差异。
- 结局证据置信度经GRADE评为极低。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,纳入RCT和观察性研究。
- 采用Cochrane协作工具和改良Newcastle-Ottawa量表评估偏倚风险,GRADE方法评估证据置信度。
- 结局证据置信度评为极低。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者结论认为,与活性对照相比,雾化氯胺酮对急性疼痛条件患者提供等效镇痛且安全性相似。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
INTRODUCTION: Ketamine administered in sub-dissociative doses has been effective in managing a variety of painful conditions in the emergency department (ED) and pre-hospital settings. The inhalation route of ketamine administration has gained traction over the past 5 years.
METHODS: We conducted a systematic review and meta-analysis to evaluate the analgesic efficacy and incidence of adverse effects of nebulized ketamine. We searched Ovid CENTRAL, EMBASE, and MEDLINE databases for randomized controlled trials (RCTs) and observational studies from inception to January 2025, assessing pain reduction, rescue analgesia, and occurrences of adverse effects. We used the Cochrane Collaboration tool and a modified Newcastle-Ottawa Scale to evaluate the risk of bias and the GRADE approach (Grading of Recommendations Assessment, Development and Evaluation) to evaluate the confidence in the evidence. Mean differences with 95 % confidence intervals (CI) using random effects were used for the meta-analyses.
RESULTS: Thirteen studies met the inclusion criteria. Nebulized ketamine had equivalent efficacy to active controls in 8 RCT's. Four RCTs (n = 601) demonstrated no difference in pain reduction between nebulized ketamine and IV morphine with mean difference (MD) 0.28 (CI -0.18 to 0.73) at 30 min, and similar rates of rescue analgesia (16.9 % vs. 17.4 %). Eleven studies reported absence of serious events and no difference in non-serious adverse events (39.1 % ketamine and 37.8 % controls). The level of confidence for the outcomes was deemed to be very low.
CONCLUSION: Administration of ketamine via nebulization for patients with acute painful conditions provided equivalent analgesia with similar safety profile when compared to active controls.
CLINICALTRIALS: gov Registration: N/A.
参考来源
- Cetin M, Brown CS, Bellolio F, et al. Nebulized ketamine for acute pain management in the Emergency Department: A systematic review and meta-analysis. Am J Emerg Med. 2025. PMID: 40286525. doi:10.1016/j.ajem.2025.04.051
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。